Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381605 | 0.95 | BDKRB1 (0.41) | BDKRB1F2NISCHHDAC4HDAC10 | |
| Trifluoroacetic Acid SCHEMBL5385915 | 0.95 | BDKRB1 (0.40) | BDKRB1F2NISCHHDAC4HDAC10 | |
| SCHEMBL5393837 | 0.91 | BDKRB1 (0.48) | BDKRB1NISCH | |
| Trifluoroacetic Acid SCHEMBL5388730 | 0.90 | BDKRB1 (0.40) | BDKRB1F2NISCH | |
| SCHEMBL5377240 | 0.86 | BDKRB1 (0.55) | BDKRB1F2NISCH | |
| Trifluoroacetic Acid SCHEMBL5388819 | 0.86 | BDKRB1 (0.44) | BDKRB1NISCH | |
| SCHEMBL5385014 | 0.86 | BDKRB1 (0.48) | BDKRB1NISCH | |
| SCHEMBL5377261 | 0.86 | BDKRB1 (0.53) | BDKRB1NISCH | |
| SCHEMBL5376846 | 0.86 | BDKRB1 (0.51) | BDKRB1NISCH | |
| Hydrochloric Acid SCHEMBL5385641 | 0.85 | BDKRB1 (0.52) | BDKRB1NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | claimed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | claimed |
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | BDKRB1 1/4885F2 106/4885NISCH 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.